Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy

Overview

Cinobufacini has the effects of anticancer, improving the liver function, elevation of immunity and little side effects, and is important and significant for the patients with hepatitis, liver cirrhosis and hepatomas. Compared with transarterial chemoembolization (TACE) , the clinical effect of cinobufacini is non-inferior/ equivalent.Compared with TACE, cinobufacini is superior in security .

Full Title of Study: “The Clinical Research of the Intermediate and Advanced Hepatoma Treated by Cinobufacin by Perfusion of Hepatic Artery Combining the Arterial Embolotherapy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: October 2013

Detailed Description

Inclusion criterion : 1. The sex does not limit, age:18-70 years old . 2. The patients have inoperable advanced hepatoma without serious disorder in liver and renal, tumor occupation< 70 % 3. The patients have failure in surgical intervention or resection operation recidivist 4. Hepatic function Child-pugh A、B 5. All the cases have the definite final diagnosis of imageology results such as MRI、CT 、B ultrasonic or cytology results 6. The patient's prediction of live time>6 months, who can tolerant of TACE and has quality of life ECOG score<3 7. The patients participate the clinical trial voluntarily and have already signed informed consent Exclusion criterion : 1. Main portal vein was obstructed completely. 2. The occupation of tumor are 70 % or more than 70 % in the whole liver 3. The patient has TACE or other antineoplaston 4. After carcinosectomy the patient has the prophylactic 5. The patient is with renal inadequacy: Cr≥133 umol/L 6. Severe cardiovascular disease 7. The patient is with other diseases to influence the proposal

Interventions

  • Drug: Cinobufacin injection
    • Cinobufacin by Perfusion of Hepatic Artery Combining the Arterial Embolotherapy

Clinical Trial Outcome Measures

Primary Measures

  • The evaluation of the patient’s respondence for the therapy is carried out every phase, according to RECIST:CR,PR,SD and PD.
    • Time Frame: Nov. 2010 to Nov. 2013
    • The evaluation of the patient’s respondence for the therapy is carried out every phase, according to RECIST:CR,PR,SD and PD.

Participating in This Clinical Trial

Inclusion Criteria

1. The sex does not limit, age:18-70 years old ; 2. The patients have inoperable advanced hepatoma without serious disorder in liver and renal, tumor occupation< 70 %; 3. The patients have failure in surgical intervention or resection operation recidivist; 4. Hepatic function Child-pugh A、B; 5. All the cases have the definite final diagnosis of imageology results such as MRI、CT 、B ultrasonic or cytology results ; 6. The patient's prediction of live time>6 months, who can tolerant of TACE and has quality of life ECOG score<3; 7. The patients participate the clinical trial voluntarily and have already signed informed consent. Exclusion Criteria:

1. Main portal vein was obstructed completely; 2. The occupation of tumour are 70 % or more than 70 % in the whole liver; 3. The patient has recepted TACE or other antineoplaston; 4. After carcinosectomy the patient has the prophylactic; 5. The patient is with renal inadequacy: Cr≥133 umol/L 6. Severe cardiovascular disease; 7. The patient is with other diseases to influence the proposal; 8. All over the body generally have metabasis or be with other malignant neoplastic disease; 9. In the process of participation of other medicinal trial; 10. Gravidity, lactation ,hypersensitiveness constitution or have already known adverse reaction or taboo.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Changhai Hospital
  • Provider of Information About this Clinical Study
    • Changquan Ling, Department of TCM, Shanghai Changhai Hospital
  • Overall Official(s)
    • Ling chang quan, doctor, Principal Investigator, Changhai Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.